Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie is currently recruiting participants for a Phase 2 study titled ‘A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis.’ The study aims to evaluate the efficacy and safety of targeted therapies for treating active psoriatic arthritis, a condition characterized by joint pain and swelling due to immune system attacks on healthy cells.
The interventions being tested include risankizumab and lutikizumab, both administered via subcutaneous injection. Participants will be randomized into three groups: lutikizumab monotherapy, risankizumab monotherapy, or a combination of both. The study will involve around 120 participants across 40 global sites.
The study design is interventional with a randomized allocation and a parallel intervention model. There is no masking involved, and the primary purpose is treatment. This setup aims to provide clear insights into the effectiveness of the therapies being tested.
The study officially started on April 11, 2025, with the latest update submitted on July 14, 2025. These dates are crucial as they mark the progression and current status of the study, which is still in the recruiting phase.
From a market perspective, this study could significantly impact AbbVie’s stock performance and investor sentiment, especially if the results demonstrate the effectiveness of the therapies. The study’s outcome may also influence the competitive landscape in the treatment of psoriatic arthritis.
The study is ongoing, with further details available on the ClinicalTrials portal.